Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM
Axsome Therapeutics (AXSM) Stock Price & Analysis
1,782 Followers
AXSM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$55.02 - $98.40
Previous Close$73.43
Volume668.11K
Average Volume (3M)661.41K
Market Cap
$3.49B
Enterprise Value$3.34B
Total Cash (Recent Filing)$331.44M
Total Debt (Recent Filing)$188.80M
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Aug 05, 2024EPS Estimate
-$1.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.38
Shares Outstanding47,495,827
10 Day Avg. Volume526,451
30 Day Avg. Volume661,409
Standard Deviation0.31
R-Squared0.04
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)43.41
Price to Sales (P/S)12.89
Price to Cash Flow (P/CF)-16.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue13.36
Enterprise Value/Gross Profit13.68
Enterprise Value/Ebitda-12.11
Forecast
1Y Price Target
$120.70Price Target Upside64.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Axsome Therapeutics News
Bulls Say, Bears Say
Bulls Say
Drug Approval And Sales PerformanceAuvelity was approved for the treatment of major depressive disorder, and strong sales figures are reported with $53M in the first quarter post-launch, indicating market acceptance and demand.
Long-term Sales OutlookAuvelity's sales are projected to grow significantly, with expectations to surpass $1 billion by 2027, showing confidence in the drug's market potential.
Market Penetration And GrowthAuvelity has achieved thousands of new patient starts and prescriber engagements shortly after its commercial launch, reflecting a successful market introduction and adoption.
Bears Say
Cybersecurity IncidentA ransomware attack at Change Healthcare had a meaningful negative impact on total prescriptions nationwide.
Financial PerformanceAnalyst estimates for Auvelity's 1Q24 revenue are 6% below the Bloomberg consensus.
Market AccessibilityTwo of the largest PBMs, CVS Health and Cigna, are not covering Auvelity.
---
Ownership Overview
0.51% Insiders
17.06% Mutual Funds
52.36% Other Institutional Investors
30.08% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AXSM FAQ
What was Axsome Therapeutics Inc’s price range in the past 12 months?
Axsome Therapeutics Inc lowest stock price was $55.02 and its highest was $98.40 in the past 12 months.
What is Axsome Therapeutics Inc’s market cap?
Currently, no data Available
When is Axsome Therapeutics Inc’s upcoming earnings report date?
Axsome Therapeutics Inc’s upcoming earnings report date is Aug 05, 2024 which is in 64 days.
How were Axsome Therapeutics Inc’s earnings last quarter?
Axsome Therapeutics Inc released its earnings results on May 06, 2024. The company reported -$1.44 earnings per share for the quarter, missing the consensus estimate of -$1.205 by -$0.235.
Is Axsome Therapeutics Inc overvalued?
According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued.
Does Axsome Therapeutics Inc pay dividends?
Axsome Therapeutics Inc does not currently pay dividends.
What is Axsome Therapeutics Inc’s EPS estimate?
Axsome Therapeutics Inc’s EPS estimate is -$1.3.
How many shares outstanding does Axsome Therapeutics Inc have?
Axsome Therapeutics Inc has 47,495,827 shares outstanding.
What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?
Axsome Therapeutics Inc reported an EPS of -$1.44 in its last earnings report, missing expectations of -$1.205. Following the earnings report the stock price went up 1.524%.
Which hedge fund is a major shareholder of Axsome Therapeutics Inc?
Among the largest hedge funds holding Axsome Therapeutics Inc’s share is Fairmount Funds Management Llc. It holds Axsome Therapeutics Inc’s shares valued at 188M.
---
Axsome Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$120.70 (64.37% Upside)
$120.70 (64.37% Upside)
Blogger Sentiment
Bullish
AXSM Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 172.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.47%
12-Months-Change
Fundamentals
Return on Equity
-231.68%
Trailing 12-Months
Asset Growth
40.23%
Trailing 12-Months
Company Description
Axsome Therapeutics Inc
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
---
AXSM Earnings Call
Q1 2024
0:00 / 0:00
---
AXSM Stock 12 Month Forecast
Average Price Target
$120.70
▲(64.37% Upside)
Technical Analysis
Best Analysts Covering AXSM
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+42.27%
reiterated a buy rating 27 days ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +42.27% per trade.
---